CPH2 Pivots to Capital-Light Licensing After Testing Incident and Fundraise

The purity numbers are also strong. CPH2 says it produced hydrogen in excess of 99.999vol% purity and oxygen at 99.7wt% purity. It says the hydrogen exceeds fuel cell grade purity under ISO 14687, while the oxygen exceeds medical grade purity.

Why does that matter? Because higher purity broadens the range of end markets and gives customers two potentially valuable outputs – hydrogen and oxygen. In simple terms, if both gases can be sold at attractive prices, project economics get better.

The May 2026 electrolyser incident changed the CPH2 investment case overnight

Now for the obvious problem. In May 2026, during the third and final stage of Factory Acceptance Testing, or FAT, on its first 1MW MFE220 unit, an incident caused structural damage to the electrolyser.

The company says initial investigations suggest its proprietary membrane-free stack and separators were not the cause. That is helpful, because those are core parts of the CPH2 technology story. But it does not remove the seriousness of the incident.

The chairman said an internal assessment indicates that a hydrogen-oxygen mixture ignited during automated depressurisation, causing a loss of containment. No one was injured, which is the most important point operationally, but the unit remains non-operational until a formal root cause analysis is approved by the board.

That independent third-party analysis is due by 31 August 2026. Until then, there is still uncertainty over what exactly failed and how expensive or time-consuming the fix will be.

CPH2 pivot to capital-light licensing: smart move or forced retreat?

My read is that this is both sensible and forced. Sensible because manufacturing and testing electrolysers is expensive, slow, and risky for a business of this size. Forced because after the incident, cash burn and execution risk became much harder to justify.

CPH2 now wants to become a global technology development and licensing company. In practice, that means focusing on research and development, stack manufacture, and licensing out its designs and know-how to partners who handle more of the heavy lifting.

There is logic to that. The company says it has been granted 16 patents across 12 jurisdictions, with a further 17 patents pending. It also says it has contractual licensing arrangements with three companies covering 12 countries.

If the technology is genuinely differentiated, a capital-light model could be a much better fit than trying to build a full manufacturing footprint itself. The catch is that licensing stories are only as good as the quality of the partners and the conversion of early agreements into real revenue.

Hidrigin, Siemens, Koch and ABE: strong names, but investors should note the small print

CPH2 has stacked up a decent list of industry names. Post year end, it announced non-binding memoranda of understanding, or MoUs, with Siemens, Koch Modular Process Systems and ABE Gruppe.

That sounds encouraging, and commercially it is. Big names do not spend time if they see no potential. But investors should stay disciplined here – non-binding MoUs are not firm contracts, not firm orders, and not guaranteed revenue.

More tangible is the binding term sheet with Hidrigin announced on 25 June 2026. That includes a proposed £750,000 convertible loan note, subject to conditions, and a nine-month exclusivity arrangement to negotiate a strategic partnership and manufacturing and technology development agreement.

There is also existing licensing momentum. During 2025, CPH2 submitted manufacturing and design licence packages to Hidrigin, Jones Engineering and Bentec, part of Helmerich & Payne. That suggests the licensing model was not invented overnight – it was already taking shape.

CPH2 fundraise and going concern warning: this is the financial risk investors cannot ignore

This is the part private investors need to read carefully. CPH2 announced a fundraise on 1 July 2026 including a firm placing and subscription for £2.5 million gross, plus a further placing, subscription and retail offer of up to £7.5 million gross, subject to a general meeting.

The board says the first tranche provides short-term liquidity. But for the full going concern period – meaning whether the business can keep operating for at least the next 12 months – completion of the second tranche is required.

That is why the accounts include a material uncertainty related to going concern. In plain English, the directors believe the company can continue, but part of the funding needed is not yet fully within its control because shareholders still need to approve it.

This does not mean failure is inevitable. It does mean dilution risk is real, financing risk is real, and the balance sheet still needs support.

What to make of the 5MW electrolyser plan and 48kWh/kg efficiency target

CPH2 says it has started front-end engineering design, or FEED, on a 5MW unit and that initial engineering assessment suggests both the 5MW and later generation 1MW units can achieve 48kWh/kg efficiency. If delivered, management believes that would be class-leading.

That is promising, but investors should treat it as early-stage engineering guidance rather than bankable commercial proof. The incident on the 1MW unit shows exactly why scaling up novel industrial hardware is rarely a straight line.

My verdict on Clean Power Hydrogen shares after these FY25 results

The positive case is clear enough. CPH2 has real intellectual property, a validated customer-site breakthrough for the MFE110, strong purity metrics, and a growing network of partners and licensees. The pivot to a licensing-led strategy could lower cash burn and make the business more scalable.

The negative case is just as clear. The 1MW testing incident is serious, revenue remains not disclosed in these highlights as a meaningful growth engine, cash burn is still heavy, and the company needs shareholder-backed funding to support the going concern outlook.

So this RNS does not read like a clean growth update. It reads like a reset. If management can turn technical credibility into licensing income, the new strategy could be the right move at the right time. If not, investors may look back at this as the moment CPH2 shifted because it had little choice.

For now, the next key marker is 31 August 2026, when the independent analysis of the incident is due. That should tell investors whether this is a painful delay or a deeper technical setback.